Effects of Melatonin Administration on Post-Stroke Delirium in Patients with Intracerebral Hemorrhage
by
, , ,
Vasileios Siokas
1,2,3,†,
Sara Roesch
1,2,†,
Maria-Ioanna Stefanou
1,2,
Rebecca Buesink
1,2,
Vera Wilke
1,2,
Jennifer Sartor-Pfeiffer
1,2,
Kamaldeen Adeyemi
1,2,
Sven Poli
1,2,
Efthimios Dardiotis
3
,
Ulf Ziemann
1,2,
Katharina Feil
1,2 and
Annerose Mengel
1,2,* 1
Department of Neurology & Stroke, Eberhard-Karls University of Tübingen, 72076 Tuebingen, Germany
2
Hertie Institute for Clinical Brain Research, Eberhard-Karls University of Tuebingen, 72076 Tuebingen, Germany
3
Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece
*
Author to whom correspondence should be addressed.
†
Shared first Authorship.
J. Clin. Med. 2023, 12(5), 1937; https://doi.org/10.3390/jcm12051937
Submission received: 27 January 2023
/
Revised: 23 February 2023
/
Accepted: 24 February 2023
/
Published: 1 March 2023
(This article belongs to the Special Issue Delirium in ICU)
Abstract
:Post-stroke delirium (PSD) after intracerebral hemorrhage (ICH) is considered to be even more detrimental compared to that after ischemic stroke. Treatment options for post-ICH PSD remain limited. This study aimed at investigating to what extent prophylactic melatonin administration may have beneficial effects on post-ICH PSD. We performed a mono-centric, non-randomized, non-blinded, prospective cohort study, including 339 consecutive ICH patients admitted to the Stroke Unit (SU) from December 2015 to December 2020. The cohort consisted of ICH patients who underwent standard care (defined as the control group) and ICH patients who additionally received prophylactic melatonin (2 mg per day, at night) within 24 h of ICH onset until the discharge from the SU. The primary endpoint was post-ICH PSD prevalence. The secondary endpoints were: (i) PSD duration and (ii) the duration of SU stay. The PSD prevalence was higher in the melatonin treated cohort compared to the propensity score-matched (PSM) control group. Post-ICH PSD patients receiving melatonin had shorter SU-stay durations, and shorter PSD durations, although not statistically significant. This study shows no efficacy in limiting post-ICH PSD with preventive melatonin administration.
1. Introduction
Post-stroke delirium (PSD) represents a severe complication of intracerebral hemorrhage (ICH) [1,2,3]. The prevalence of PSD is higher in patients with ICH compared to those with acute ischemic stroke (AIS) [4,5], with a reported frequency of 59% [2,6,7,8,9]. Post-ICH PSD develops 3 to 5 days later compared to post-AIS PSD [2,10,11]. Post-ICH PSD has been associated with increased in-hospital and 5-year mortality, prolonged intensive care unit (ICU) stay, worse functional and neurological outcomes, and worse quality of life [2,6,7].
The pathogenetic processes behind the development of post-ICH PSD are poorly understood. Defective neuronal connectivity and neurotransmission, impaired brain metabolism, neuroinflammation, disturbed sleep–wake cycles, abnormal oxygen supply, electrolytic disturbances, overt stress responses, altered cellular signaling, and brain vascular dysfunction are considered to be implicated in PSD development [12,13,14]. Despite the fact that several predisposing factors have been incriminated in increasing the risk of post-ICH PSD, the extent of their contribution to PSD has not yet been fully elucidated [2,6,15].
Melatonin is a hormone secreted by the pineal gland, and in clinical practice exogenous melatonin supplementation is used mainly for, but not limited to, treating sleep disorders [16]. The hypothesis of a pathophysiological implication of melatonin in delirium derives from its connection to disturbed sleep–wake systems [17], the disruption of which is a core characteristic of delirium [18]. Moreover, there is accumulating evidence in the literature for differences in melatonin levels in patients with delirium compared to healthy subjects [19,20,21].
With respect to the therapeutic efficacy of melatonin, conflicting data have been reported. Previous studies have indicated that melatonin supplementation may be effective in preventing delirium, however, there are also studies reporting no benefit thereof [22,23]. Exogenous melatonin was associated with a significant attenuation of PSD risk in AIS, and consequently with improved clinical outcomes in PSD stroke patients [24]. While there are no large studies today on the effects of melatonin on post-ICH PSD, there is some evidence that melatonin supplementation may improve clinical outcomes (duration of mechanical ventilation, length of ICU stay, clinical manifestations) in ICH patients [25,26].
In view of the former considerations, we hypothesized that preventive administration of melatonin will decrease the frequency of post-ICH PSD and also demonstrate beneficial effects on related outcomes (e.g., PSD duration and SU-stay duration). As such, the aim of the present study in a cohort of ICH patients was to examine the effect of preventive administration of melatonin on post-ICH PSD prevalence. We also examined the effect of preventive administration of melatonin on PSD duration and SU-stay duration.
2. Materials and Methods
2.1. Study Design and Regulations
We conducted a mono-centric, non-randomized, non-blinded, prospective cohort study. Our cohort consisted of ICH patients who were prophylactically treated with melatonin for PSD prevention versus non-treated ICH patients (defined as the control group). The institutional ethics committee approved the protocol of the study (protocol number 752/2018BO2). Due to the clinic-wide consent regarding the use of de-identified routine treatment data for research purposes, the individual informed consent from the participants was waived.
2.2. Study Population
Consecutive ICH patients admitted to the stroke unit (SU) of the University Hospital of Tübingen, between 1 December 2015 and 31 December 2020 were included. All patients were diagnosed with nontraumatic ICH according to the International Classification of Diseases, 10th Revision I61.
2.3. Participants’ Exclusion Criteria
The following exclusion criteria were applied: (1) duration of SU stay <24 h; (2) diagnosis of delirium caused by benzodiazepines on admission (oa); (3) a Richmond Agitation-Sedation Scale (RASS) level of −5 or −4 for the majority (>50%) of the stay; (4) patients on mechanical ventilation or in shock or who had severe liver or renal insufficiency; (5) an incomplete record of the RASS and Intensive Care Delirium Screening Checklist (ICDSC) during the stay; (6) patients who underwent neurosurgical intervention immediately after baseline-CT; (7) patients with traumatic ICH.
2.4. Melatonin Administration
All treated patients underwent prophylactic melatonin supplementation according to the standard operating procedure (SOP) of the SU for PSD prevention, which has previously been described in detail [24].
In brief, the rationale for preventive application of melatonin in the SOP were: (i) the lack of clear evidence regarding therapeutic options for PSD prevention and management; (ii) melatonin’s excellent tolerability and safety profile; and (iii) evidence regarding the beneficial effect of melatonin in delirium prevention in elderly, in stroke patients, and in ICU patients [24,25,26,27]. The treated cohort received melatonin orally (and in case of severe dysphagia administered through a nasogastric tube) within the first 24 h of ICH onset (single dose of 2 mg/day at 8 p.m.) [28] until discharge from the SU.
2.5. Data Collection
The baseline characteristics, personal medical history, and in-hospital clinical parameters for all the participants were retrieved from the clinical information system (Intellispace Critical Care and Anesthesia information system; Philips Healthcare). Data from head neuroimaging (CT or MRI) on admission were also obtained.
We applied the ICDSC in order to assess PSD in all participants (both melatonin-treated and control cohort) [1]. The ICDSC scores were recorded on admission and every 8 h (morning, afternoon, and night) during the whole SU stay, from trained neurocritical care nurses. Participants were considered to have PSD in case of ISDSC ≥4 for non-aphasic and ≥5 for aphasic patients [1,29], while the first pathological score was indicative of the PSD onset. The diagnosis of PSD was made based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, by neurologists blinded to the ICDSC scores [24]. The validity and reliability of ICDSC in measuring delirium in stroke patients have been assessed in a previous study [1]. Data regarding PSD duration during the SU stay were also gathered.
The following data were collected for each participant: age, sex, history of hypertension (HP), history of diabetes mellitus (DM), history of hypercholesterolemia (HCL), history of atrial fibrillation (AF), history of coronary artery disease (CAD), obesity (defined as body mass index [BMI] > 30), chronic renal failure, chronic hepatic failure, history of smoking, history of alcohol consumption, history of malignancy, history of depression, cognitive status (normal cognition vs. mild cognitive impairment (MCI/dementia)), infections during stay at SU, NIHSS oa, presence of aphasia oa, ICH-score oa, modified Rankin scale (mRS) before the index event, the etiology of ICH (hypertension, cerebral amyloid angiopathy (CAA), mass (benign and non-benign), oral anticoagulant (OAC), vessel pathology, other/unknown), hemorrhagic location at baseline (deep white matter (DWM), lobar, brainstem, cerebellum, left or right hemisphere), intraventricular hemorrhage (IVH) oa, IVH extension, ICH volume (expressed as cm3), invasive procedures (surgical evacuation and external ventricular drain [30]), and SU-stay duration.
2.6. Study Endpoints
The primary endpoint of the current study was the effect of preventive melatonin application on post-ICH PSD prevalence. The secondary endpoints were the effects of melatonin administration on PSD duration and SU-stay duration.
2.7. Statistical Analysis
To minimize selection bias of the retrospective analysis, propensity score matching (PSM) with a match tolerance of 0.2 was performed in order to balance baseline differences in clinical covariates between patients treated with melatonin and controls. Standardized mean differences (SMD) were calculated to compare participant features after PSM. SMD values greater than 0.25 were considered indicative for imbalance [31,32].
We used the Shapiro–Wilk test to check the distribution of the data. For categorical variables, the differences between groups regarding demographics and clinical characteristics were assessed using Pearson’s chi-squared test. For continuous variables, we applied Mann–Whitney U tests due to non-normal distribution of the data. Values are expressed as total number (n) with the respective percentage (%) for categorical variables. For continuous variables, values are expressed as medians with the respective interquartile ranges (IQR).
We used chi-square tests to examine the difference in post-ICH PSD prevalence, between the melatonin-treated cohort and the control group. To better capture the treatment effect on each group (for descriptive purposes) between group differences regarding PSD duration and SU-stay duration, we applied Mann–Whitney U tests. For the effect of the preventive administration of melatonin on the PSD duration (hours) and SU-stay duration (hours), we applied linear regression analyses, using melatonin treatment as predictor, after logarithmic transformation of the dependent variables (i.e., PSD duration and SU-stay duration) due to non-normal distribution of the data. Adjusted models for the variables that differed between groups or correlated with the outcome of interest in univariate analysis, were also performed. The multicollinearity was assessed by using the variance inflation factor (VIF). VIF values of 10 were considered as cut points for the elimination variable from the model [33]. No multicollinearity was detected (VIF < 10) in any of the analyses.
For the statistically significant results, we also performed sensitivity analyses by excluding patients that died during hospitalization, aiming to eliminate any possible latent effect of this factor on the PSD duration or SU-stay duration.
An alpha error of 5% (p < 0.05) was set as the level of statistical significance for all procedures. All statistical analyses were performed with SPSS (Version 29, IBM, Armonk, NY, USA).
3. Results
3.1. Participants’ Characteristics and Post-ICH PSD Prevalence
In total, 339 patients with ICH were included in this study. Out of the 339 ICH patients, 127 (37.5%) developed PSD during the SU stay. The majority of them (74.2%) developed PSD within the first 48 h of admission, whereas the vast majority of them (∼90%) developed PSD within the first 120 h after admission (Figure S1). Median of PSD onset was 27.5 h (IQR, 44), and its median duration was 144 h (IQR, 157). The post-ICH PSD cohort was older and had higher NIHSS and ICH-scores oa, compared to their non-PSD counterparts. Moreover, we found an increased prevalence of AF, infections during SU stay, IVH extension, hypertension, and OAC as etiology of ICH in the post-ICH PSD cohort. The vessel pathology as etiology for ICH was more prevalent in non-PSD patients. Patients’ characteristics are presented in Table 1.
3.2. Effect of Melatonin Administration on PSD Prevention
The melatonin-treated cohort had lower NIHSS, ICH-scores, and ICH-volume oa, increased prevalence of HCL, OAC as etiology of ICH, and decreased prevalence of EVD, surgical evacuation, and IVH extension compared to the control group. After the PSM, no statistically significant between-group differences in characteristics were noted, with the exception of brainstem location of ICH at baseline, which was higher in the control group. Patients’ characteristics, based on receiving (or not) melatonin, are presented in Table 2.
The PSD prevalence was higher in the melatonin-treated cohort (47.9%) compared to the control group (31.8%, p = 0.004), and compared to the PSM control group (26.3%, p < 0.001).
3.2.1. Effect of Melatonin Administration on PSD Duration
Post-ICH PSD patients’ characteristics, based on receiving (or not) melatonin after the PSM in the initial sample (n = 88) are presented in Table 3. No statistically significant between-group differences in characteristics were noted, with the exception of NIHSS oa, which was statistically significant higher in the control group.
In PSD patients, preventive melatonin administration did not correlate with duration of PSD in neither crude (b, −0.189; 95% CI, −0.407 to 0.029; p = 0.088) nor adjusted models (b, −0.071; 95% CI, −0.273 to 0.131; p = 0.436). Adjustment was made for variables that significantly correlated with PSD duration, as presented at Table S1, or differed between treated and control PSD group (Table 3). Results regarding the effect of preventive administration of melatonin on PSD duration (unadjusted and adjusted analyses) are summarized in Table 4. Median duration of delirium in PSD patients receiving melatonin was 124 h (IQR, 151), and 176 h (IQR, 186) in the control group (p-value for Mann–Whitney U test = 0.104). Box plots presenting data for PSD duration (hours) with respect to administration (or not) of melatonin are shown in Figure 1.
3.2.2. Effect of Melatonin Administration on SU-Stay Duration
Post-ICH PSD Patients
Melatonin administration was negatively correlated with SU-stay duration of PSD patients (b, −0.147; 95% CI, −0.278 to −0.016; p = 0.028). The significance did not remain in the adjusted model (b, −0.094; 95% CI, −0.207 to 0.020; p = 0.104). Adjustment was made for variables that significantly correlated with SU-stay duration, as presented in Table S2 or differing between treated and control PSM PSD groups (Table 3). Median SU-stay duration of PSD patients receiving melatonin was 184 h (IQR, 154), and 274 h (IQR, 285) in the PSD control group (p-value for Mann–Whitney U test = 0.033). Box plots presenting data for SU-stay duration (hours) in respect to administration (or not) of melatonin in PSD are shown in Figure 2.
However, the significance did not remain in the sensitivity analysis, after excluding patients who died during hospitalization (p-value for Mann–Whitney U test = 0.051), although post-ICH PSD patients receiving melatonin had lower SU-stay duration compared to the control group (187 h vs. 274 h) (Figure S2).
Post-ICH without PSD Patients
Post-ICH without PSD patients’ characteristics, based on receiving (or not) melatonin after the PSM in the initial sample (n = 149), are presented in Table S3. Melatonin administration was not associated with SU-stay duration of non-PSD patients in both crude (b, −0.004; 95% CI, −0.114 to 0.123; p = 0.941) and adjusted (b, 0.031; 95% CI, −0.60 to 0.131; p = 0.460) models. Adjustment was made for variables that significantly correlated with SU-stay duration, as presented in Table S2, or differed between treated and control PSM non-PSD groups (Table S3). Median SU-stay duration of non-PSD patients receiving melatonin was 108 h (IQR, 161), and 109 h (IQR, 154) in the non-PSD control group (p-value for Mann–Whitney U test = 0.910). Box plots presenting data for SU-stay duration (hours) in respect to administration (or not) of melatonin in non-PSD are shown in Figure S3.
Results regarding the effect of preventive administration of melatonin on SU-stay duration (unadjusted and adjusted analyses) are summarized in Table 5.
4. Discussion
In this cohort study, we investigated the potential preventive effect of low-dose melatonin on PSD. The PSD prevalence was higher in the melatonin cohort compared to control group. Since age of treated patients was slightly higher compared to controls after PSM (76 vs. 74.5 years), it may comprise a possible reason for these results. Moreover, the lack of a preventive effect of melatonin on PSD prevalence may be attributed to the low melatonin dosage in our study, especially when it is compared to melatonin dosages of previous studies reporting a beneficial effect of melatonin on ICH [25,34].
The preventive administration of melatonin had marginal beneficial effects on SU-stay duration and on PSD duration in post-ICH patients. More precisely, the post-ICH patients receiving melatonin appeared to have shorter, but not statistically significant, PSD duration compared to untreated patients. Of note, in our study, median SU-stay duration of PSD patients receiving melatonin was shorter compared to the PSD control group, highlighting a possible beneficial effect of the preventive melatonin administration in ICH patients. In particular, the median SU-stay duration of PSD patients receiving melatonin was reduced by more than 3.5 days compared to their non-treated PSD counterparts. Considering this, we could hypothesize that melatonin may have a beneficial effect only on specific PSD parameters, while higher melatonin dosages may be required for preventive effects on PSD prevalence to become evident.
The vast majority of post-ICH PSD patients (~90%) developed PSD within the first 120 h after admission. By contrast, one previous report [24] suggests that post-AIS PSD manifests earlier compared to post-ICH PSD. The vast majority of AIS patients (96.7%) developed PSD within the first 72 h [24]. A possible explanation for these findings could be that secondary ischemic/hypoxic dysfunction in tissue surrounding the ICH, may lead to a delayed PSD occurrence in ICH compared to AIS, albeit the exact pathophysiological mechanisms remain to be elucidated [35,36]. Delayed post-ICH PSD development and overlapping clinical features with ICH [2] suggest that physicians should be alerted to detect PSD in ICH patients during almost their entire stay in SU.
Among the strengths of our study is the inclusion of a large number of well-characterized ICH patients, following a standardized protocol for PSD detection. Secondly, we performed multivariate analyses with adjustment for a large amount of potential cofounding factors, sensitivity analyses for the statistically significant results, and mainly a PSM analysis in an attempt to minimize any possible selection bias. At this point we must also acknowledge the limitations of our study. Firstly, we did not randomize the sample for melatonin administration and the generalizability of our results is limited, despite our approach of using PSM analysis. Thus, the present findings require validation from a prospective randomized controlled trial (RCT). Moreover, given the different pathophysiological mechanisms implicated in different PSD subtypes [37], additional studies in subclusters of patients based on PSD subtype, will allow us to draw more robust conclusions regarding the effect of melatonin on post-ICH PSD.
5. Conclusions
This study shows no efficacy in limiting post-ICH PSD with preventive melatonin administration, as the PSD prevalence was higher in the melatonin cohort. However, the preventive administration of melatonin appears to have marginal beneficial effects on SU-stay duration and on PSD duration in post-ICH PSD. Yet, due to methodological limitations related to the non-randomized study design, we cannot totally exclude that the utility of melatonin may have been underestimated. Taking into consideration the limited available therapeutic strategies for PSD, large-scale RCTs are warranted to further test and validate the role of melatonin in preventing and treating post-ICH PSD.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12051937/s1, Table S1: Analysis for effect of factors on PSD duration; Table S2: Analysis for effect of factors on SU-stay duration; Table S3: Post-ICH without PSD patients’ characteristics treated with melatonin vs. the control cohort after propensity matching; Figure S1: Cumulative post-stroke delirium prevalence (line) and point prevalence (bar plot); Figure S2: Box plots presenting data for stroke unit stay duration (hours) in respect to administration (or not) of melatonin in post-intracerebral hemorrhage patients with post-stroke delirium, who did not die during hospitalization; Figure S3: Box plots presenting data for stroke unit stay duration (hours) with respect to administration (or not) of melatonin in post-intracerebral hemorrhage patients without post-stroke delirium.
Author Contributions
Conceptualization, A.M.; methodology, V.S., S.R., M.-I.S., S.P., K.F. and A.M.; validation, V.S., S.R., M.-I.S., R.B., V.W., J.S.-P., K.A., S.P., E.D., U.Z., K.F. and A.M.; formal analysis, V.S., S.R., K.F. and A.M.; investigation, V.S., S.R., M.-I.S., R.B., V.W., J.S.-P., K.A., K.F. and A.M.; data curation, V.S., S.R., M.-I.S. and A.M.; writing—original draft preparation, V.S., S.R., M.-I.S. and A.M.; writing—review and editing, V.S., S.R., M.-I.S., R.B., V.W., J.S.-P., K.A., S.P., E.D., U.Z., K.F. and A.M.; supervision, A.M.; project administration, A.M. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The institutional ethics committee approved the protocol of the study (protocol number 752/2018BO2).
Informed Consent Statement
Due to the clinic-wide consent regarding the use of de-identified routine treatment data for research purposes, the individual informed consent from the participants was waived.
Data Availability Statement
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Acknowledgments
The authors are thankful for the support of the Open Access Publishing Fund of the University of Tuebingen. Vasileios Siokas is supported by a scholarship from the Hellenic Neurological Society, which played no role in the design of the study, collection and/or interpretation of data, or writing of the article.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Bosselmann, C.; Zurloh, J.; Stefanou, M.I.; Stadler, V.; Weber, Y.; Lerche, H.; Poli, S.; Ziemann, U.; Mengel, A. Delirium Screening in Aphasic Patients with the Intensive Care Delirium Screening Checklist (ICDSC): A Prospective Cohort Study. Front. Neurol. 2019, 10, 1198. [Google Scholar] [CrossRef] [PubMed]
- Naidech, A.M.; Beaumont, J.L.; Rosenberg, N.F.; Maas, M.B.; Kosteva, A.R.; Ault, M.L.; Cella, D.; Ely, E.W. Intracerebral hemorrhage and delirium symptoms. Length of stay, function, and quality of life in a 114-patient cohort. Am. J. Respir. Crit. Care Med. 2013, 188, 1331–1337. [Google Scholar] [CrossRef] [Green Version]
- Siokas, V.; Fleischmann, R.; Feil, K.; Liampas, I.; Kowarik, M.C.; Bai, Y.; Stefanou, M.I.; Poli, S.; Ziemann, U.; Dardiotis, E.; et al. The Role of Vascular Risk Factors in Post-Stroke Delirium: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 5835. [Google Scholar] [CrossRef]
- Alvarez-Perez, F.J.; Paiva, F. Prevalence and Risk Factors for Delirium in Acute Stroke Patients. A Retrospective 5-Years Clinical Series. J. Stroke Cereb. Dis. 2017, 26, 567–573. [Google Scholar] [CrossRef]
- Pasinska, P.; Kowalska, K.; Klimiec, E.; Szyper-Maciejowska, A.; Wilk, A.; Klimkowicz-Mrowiec, A. Frequency and predictors of post-stroke delirium in PRospective Observational POLIsh Study (PROPOLIS). J. Neurol. 2018, 265, 863–870. [Google Scholar] [CrossRef] [PubMed]
- Marrama, F.; Kyheng, M.; Pasi, M.; Pierre Rutgers, M.; Moulin, S.; Diomedi, M.; Leys, D.; Cordonnier, C.; Hénon, H.; Casolla, B. Early-onset delirium after spontaneous intracerebral hemorrhage. Int. J. Stroke 2021, 98, 17474930211059636. [Google Scholar] [CrossRef]
- Reznik, M.E.; Margolis, S.A.; Mahta, A.; Wendell, L.C.; Thompson, B.B.; Stretz, C.; Rudolph, J.L.; Boukrina, O.; Barrett, A.M.; Daiello, L.A.; et al. Impact of Delirium on Outcomes after Intracerebral Hemorrhage. Stroke 2022, 53, 505–513. [Google Scholar] [CrossRef]
- Sauvigny, T.; Mohme, M.; Grensemann, J.; Dührsen, L.; Regelsberger, J.; Kluge, S.; Schmidt, N.O.; Westphal, M.; Czorlich, P. Rate and risk factors for a hyperactivity delirium in patients with aneurysmal subarachnoid haemorrhage. Neurosurg. Rev. 2019, 42, 481–488. [Google Scholar] [CrossRef]
- Reimann, F.; Rinner, T.; Lindner, A.; Kofler, M.; Ianosi, B.A.; Schiefecker, A.J.; Beer, R.; Schmutzhard, E.; Pfausler, B.; Helbok, R.; et al. Hyperactive delirium in patients after non-traumatic subarachnoid hemorrhage. J. Crit. Care 2021, 64, 45–52. [Google Scholar] [CrossRef]
- Fleischmann, R.; Warwas, S.; Andrasch, T.; Kunz, R.; Witt, C.; Mengel, A.; von Sarnowski, B. Course and Recognition of Poststroke Delirium: A Prospective Noninferiority Trial of Delirium Screening Tools. Stroke 2021, 52, 471–478. [Google Scholar] [CrossRef] [PubMed]
- Dostović, Z.; Smajlović, D.; Sinanović, O.; Vidović, M. Duration of delirium in the acute stage of stroke. Acta Clin. Croat. 2009, 48, 13–17. [Google Scholar] [PubMed]
- van Gool, W.A.; van de Beek, D.; Eikelenboom, P. Systemic infection and delirium: When cytokines and acetylcholine collide. Lancet 2010, 375, 773–775. [Google Scholar] [CrossRef] [PubMed]
- Maclullich, A.M.; Ferguson, K.J.; Miller, T.; de Rooij, S.E.; Cunningham, C. Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responses. J. Psychosom. Res. 2008, 65, 229–238. [Google Scholar] [CrossRef] [Green Version]
- van Munster, B.C.; de Rooij, S.E.; Korevaar, J.C. The role of genetics in delirium in the elderly patient. Dement. Geriatr. Cogn. Disord. 2009, 28, 187–195. [Google Scholar] [CrossRef]
- Mansutti, I.; Saiani, L.; Palese, A. Delirium in patients with ischaemic and haemorrhagic stroke: Findings from a scoping review. Eur. J. Cardiovasc. Nurs. 2019, 18, 435–448. [Google Scholar] [CrossRef]
- Pohanka, M. New Uses of Melatonin as a Drug; A Review. Curr. Med. Chem. 2022, 29, 3622–3637. [Google Scholar] [CrossRef] [PubMed]
- Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharm. 2018, 175, 3190–3199. [Google Scholar] [CrossRef] [Green Version]
- Daou, M.; Telias, I.; Younes, M.; Brochard, L.; Wilcox, M.E. Abnormal Sleep, Circadian Rhythm Disruption, and Delirium in the ICU: Are They Related? Front. Neurol. 2020, 11, 549908. [Google Scholar] [CrossRef]
- Sheng, A.Z.; Shen, Q.; Cordato, D.; Zhang, Y.Y.; Yin Chan, D.K. Delirium within three days of stroke in a cohort of elderly patients. J. Am. Geriatr. Soc. 2006, 54, 1192–1198. [Google Scholar] [CrossRef]
- Shigeta, H.; Yasui, A.; Nimura, Y.; Machida, N.; Kageyama, M.; Miura, M.; Menjo, M.; Ikeda, K. Postoperative delirium and melatonin levels in elderly patients. Am. J. Surg. 2001, 182, 449–454. [Google Scholar] [CrossRef] [PubMed]
- Balan, S.; Leibovitz, A.; Zila, S.O.; Ruth, M.; Chana, W.; Yassica, B.; Rahel, B.; Richard, G.; Neumann, E.; Blagman, B.; et al. The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J. Neuropsychiatry Clin. Neurosci. 2003, 15, 363–366. [Google Scholar] [CrossRef]
- Walker, C.K.; Gales, M.A. Melatonin Receptor Agonists for Delirium Prevention. Ann. Pharm. 2017, 51, 72–78. [Google Scholar] [CrossRef]
- Ford, A.H.; Flicker, L.; Kelly, R.; Patel, H.; Passage, J.; Wibrow, B.; Anstey, M.; Edwards, M.; Almeida, O.P. The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium. J. Am. Geriatr. Soc. 2020, 68, 112–119. [Google Scholar] [CrossRef]
- Mengel, A.; Zurloh, J.; Boßelmann, C.; Brendel, B.; Stadler, V.; Sartor-Pfeiffer, J.; Meisel, A.; Fleischmann, R.; Ziemann, U.; Poli, S.; et al. Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis. Eur. J. Neurol. 2021, 28, 1958–1966. [Google Scholar] [CrossRef]
- Dianatkhah, M.; Najafi, A.; Sharifzadeh, M.; Ahmadi, A.; Sharifnia, H.; Mojtahedzadeh, M.; Najmeddin, F.; Moghaddas, A. Melatonin Supplementation May Improve the Outcome of Patients with Hemorrhagic Stroke in the Intensive Care Unit. J. Res. Pharm. Pract. 2017, 6, 173–177. [Google Scholar] [CrossRef]
- Ohta, T.; Murao, K.; Miyake, K.; Takemoto, K. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J. Stroke Cereb. Dis. 2013, 22, 1107–1110. [Google Scholar] [CrossRef]
- Hatta, K.; Kishi, Y.; Wada, K.; Takeuchi, T.; Odawara, T.; Usui, C.; Nakamura, H. Preventive effects of ramelteon on delirium: A randomized placebo-controlled trial. JAMA Psychiatry 2014, 71, 397–403. [Google Scholar] [CrossRef] [Green Version]
- Pierce, M.; Linnebur, S.A.; Pearson, S.M.; Fixen, D.R. Optimal Melatonin Dose in Older Adults: A Clinical Review of the Literature. Sr. Care Pharm. 2019, 34, 419–431. [Google Scholar] [CrossRef]
- Bergeron, N.; Dubois, M.J.; Dumont, M.; Dial, S.; Skrobik, Y. Intensive Care Delirium Screening Checklist: Evaluation of a new screening tool. Intensive Care Med. 2001, 27, 859–864. [Google Scholar] [CrossRef]
- Smyrnis, N.; Theleritis, C.; Evdokimidis, I.; Muri, R.M.; Karandreas, N. Single-pulse transcranial magnetic stimulation of parietal and prefrontal areas in a memory delay arm pointing task. J. Neurophysiol. 2003, 89, 3344–3350. [Google Scholar] [CrossRef]
- Stuart, E.A.; Lee, B.K.; Leacy, F.P. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J. Clin. Epidemiol. 2013, 66, S84–S90.e81. [Google Scholar] [CrossRef]
- Rubin, D.B. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation. Health Serv. Outcomes Res. Methodol. 2001, 2, 169–188. [Google Scholar] [CrossRef]
- Makango, B.; Alemu, Z.A.; Solomon, T.; Lemma, N.; Girma, T.; Mohammednur, T.; Alayu, M.; Fufa, Y. Prevalence and factors associated with post-traumatic stress disorder among internally displaced people in camps at Debre Berhan, Amhara Region, Ethiopia: A cross-sectional study. BMC Psychiatry 2023, 23, 81. [Google Scholar] [CrossRef]
- Soltani, F.; Salari, A.; Javaherforooshzadeh, F.; Nassajjian, N.; Kalantari, F. The effect of melatonin on reduction in the need for sedative agents and duration of mechanical ventilation in traumatic intracranial hemorrhage patients: A randomized controlled trial. Eur. J. Trauma Emerg. Surg. 2022, 48, 545–551. [Google Scholar] [CrossRef]
- Rhee, J.Y.; Colman, M.A.; Mendu, M.; Shah, S.J.; Fox, M.D.; Rost, N.S.; Kimchi, E.Y. Associations between Stroke Localization and Delirium: A Systematic Review and Meta-Analysis. J. Stroke Cereb. Dis. 2022, 31, 106270. [Google Scholar] [CrossRef]
- Ostrowski, R.P.; Stępień, K.; Pucko, E.; Matyja, E. The efficacy of hyperbaric oxygen in hemorrhagic stroke: Experimental and clinical implications. Arch. Med. Sci. 2017, 13, 1217–1223. [Google Scholar] [CrossRef]
- Evensen, S.; Bourke, A.K.; Lydersen, S.; Sletvold, O.; Saltvedt, I.; Wyller, T.B.; Taraldsen, K. Motor activity across delirium motor subtypes in geriatric patients assessed using body-worn sensors: A Norwegian cross-sectional study. BMJ Open 2019, 9, e026401. [Google Scholar] [CrossRef] [Green Version]
Figure 1.
Box plots presenting data for post-stroke delirium duration (hours) in post-intracerebral hemorrhage patients with respect to administration (or not) of melatonin. In the box plot, the black line within a box indicates the median, the boundary of the box closest to zero indicates the 1st quartile, and the boundary of the box farthest from zero indicates the 3rd quartile. Outliers with values more than 3 interquartile ranges (IQRs) from the end of the box are denoted with an asterisk (*). Outliers with values more than 1.5 IQRs, but less than 3 IQRs from the end of the box, are denoted with a circle (o). Whiskers above and below the box indicate max and min values, respectively, not including outliers. Median duration of delirium in patients receiving melatonin was 124 h, and 176 h in the control group.
Figure 1.
Box plots presenting data for post-stroke delirium duration (hours) in post-intracerebral hemorrhage patients with respect to administration (or not) of melatonin. In the box plot, the black line within a box indicates the median, the boundary of the box closest to zero indicates the 1st quartile, and the boundary of the box farthest from zero indicates the 3rd quartile. Outliers with values more than 3 interquartile ranges (IQRs) from the end of the box are denoted with an asterisk (*). Outliers with values more than 1.5 IQRs, but less than 3 IQRs from the end of the box, are denoted with a circle (o). Whiskers above and below the box indicate max and min values, respectively, not including outliers. Median duration of delirium in patients receiving melatonin was 124 h, and 176 h in the control group.
Figure 2.
Box plots presenting data for stroke-unit-stay duration (hours) in respect to administration (or not) of melatonin in post-intracerebral hemorrhage patients with post-stroke delirium. In the box plot, the black line within a box indicates the median, the boundary of the box closest to zero indicates the 1st quartile, and the boundary of the box farthest from zero indicates the 3rd quartile. Outliers with values more than 1.5 IQRs, but less than 3 IQRs from the end of the box, are denoted with a circle (o). Whiskers above and below the box indicate max and min values, respectively, not including outliers. Median stroke-unit-stay duration of post-stroke delirium patients receiving melatonin was 184 h, and 274 h in the control group (p-value for Mann–Whitney U test = 0.033).
Figure 2.
Box plots presenting data for stroke-unit-stay duration (hours) in respect to administration (or not) of melatonin in post-intracerebral hemorrhage patients with post-stroke delirium. In the box plot, the black line within a box indicates the median, the boundary of the box closest to zero indicates the 1st quartile, and the boundary of the box farthest from zero indicates the 3rd quartile. Outliers with values more than 1.5 IQRs, but less than 3 IQRs from the end of the box, are denoted with a circle (o). Whiskers above and below the box indicate max and min values, respectively, not including outliers. Median stroke-unit-stay duration of post-stroke delirium patients receiving melatonin was 184 h, and 274 h in the control group (p-value for Mann–Whitney U test = 0.033).
Table 1.
Characteristics of patients with ICH.
| Patients’ Characteristics | All ICH Patients n = 339 | ICH Patients with PSD n = 127 | ICH Patients without PSD n = 212 | p-Value |
|---|---|---|---|---|
| Demographics | ||||
| Age, y median, (IQR) | 74.00 (20.00) | 78.00 (16.00) | 71.50 (22.00) | 0.001 ^ |
| Sex, n (%) | 0.454 * | |||
| Male | 186 (54.9) | 73 (57.5) | 113 (53.3) | |
| Female | 153 (45.1) | 54 (42.5) | 99 (46.7) | |
| Risk Factors, n (%) | ||||
| HP | 268 (79.1) | 104 (81.9) | 164 (77.4) | 0.321 * |
| DM | 64 (18.9) | 27 (21.3) | 37 (17.5) | 0.386 * |
| HCL | 67 (19.8) | 28 (22.0) | 39 (18.4) | 0.414 * |
| AF | 94 (27.7) | 46 (36.2) | 48 (22.6) | 0.007 * |
| CAD | 60 (17.8) | 26 (20.5) | 34 (16.1) | 0.310 * |
| Obesity (BMI > 30) | 61 (18.0) | 22 (17.3) | 39 (18.4) | 0.803 * |
| Chronic renal failure | 38 (11.2) | 15 (11.8) | 23 (10.8) | 0.786 * |
| Chronic hepatic failure | 8 (2.4) | 2 (1.6) | 6 (2.8) | 0.461 * |
| Smoking | 46 (13.6) | 15 (11.8) | 31 (14.6) | 0.464 * |
| Alcohol | 27 (8.0) | 10 (7.9) | 17 (8.0) | 0.962 * |
| Malignancy | 36 (10.2) | 12 (9.4) | 24 (11.3) | 0.588 * |
| Depression | 21 (6.2) | 7 (5.5) | 14 (6.6) | 0.686 * |
| Cognition | 0.153 *# | |||
| Health | 301 (89.6) | 109 (86.5) | 192 (91.4) | |
| MCI | 31 (9.2) | 13 (10.3) | 18 (8.6) | |
| Dementia | 4 (1.2) | 4 (3.2) | 0 (0.0) | |
| Any kind of infection | 176 (51.9) | 85 (66.9) | 91 (42.9) | <0.001 * |
| Baseline clinical variables/scales | ||||
| NIHSS oa, median (IQR) | 7.00 (10.0) | 8.00 (9.00) | 6.00 (11.00) | 0.005 ^ |
| Aphasia oa, n (%) | 125 (37.4) | 53 (41.7) | 72 (34.8) | 0.203 * |
| ICH-score oa, median (IQR) | 1.00 (1.00) | 2.00 (1.00) | 1.00 (2.00) | <0.001 ^ |
| mRS before the ICH, median (IQR) | 0.00 (2.00) | 1.00 (2.00) | 0.00 (1.00) | 0.131 ^ |
| Etiology, n (%) | ||||
| Hypertension | 191 (56.3) | 82 (64.6) | 109 (51.4) | 0.018 * |
| CAA | 27 (8.0) | 12 (9.4) | 15 (7.1) | 0.435 * |
| Mass | 26 (7.7) | 8 (6.3) | 18 (8.5) | 0.463 |
| OAC | 92 (27.2) | 44 (34.6) | 48 (22.6) | 0.016 * |
| Vessel pathology | 20 (5.9) | 2 (1.6) | 18 (8.5) | 0.009 * |
| Other/unknown | 67 (19.8) | 21 (16.5) | 46 (21.7) | 0.248 * |
| Location at baseline, n (%) | ||||
| DWM | 157 (46.6) | 65 (51.2) | 92 (43.4) | 0.189 * |
| Lobar | 139 (41.0) | 46 (36.2) | 93 (43.9) | 0.166 * |
| Brainstem | 18 (5.3) | 4 (3.2) | 14 (6.6) | 0.172 * |
| Cerebellum | 41 (12.2) | 15 (11.8) | 26 (12.4) | 0.877 * |
| Left hemisphere | 182 (53.7) | 65 (51.2) | 117 (55.2) | 0.474 * |
| Right hemisphere | 174 (51.3) | 64 (50.4) | 110 (51.9) | 0.790 * |
| IVH oa | 5 (1.5) | 2 (1.6) | 3 (1.4) | 0.906 * |
| IVH extension | 139 (41.2) | 66 (52.4) | 73 (34.6) | 0.001 * |
| ICH Volume (cm3), median (IQR) | 11.00 (22.00) | 11.50 (23.00) | 10.50 (22.00) | 0.478 ^ |
| Invasive procedures n (%) | ||||
| Surgical evacuation | 49 (14.5) | 13 (10.2) | 36 (17.0) | 0.087 * |
| EVD | 49 (14.5) | 24 (18.9) | 25 (11.8) | 0.078 * |
ICH, intracerebral hemorrhage; PSD, post-stroke delirium; HP; hypertension; DM, diabetes mellitus; HCL, hypercholesterolemia; AF, atrial fibrillation; CAD, coronary artery disease; BMI, body mass index; MCI, mild cognitive impairment; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin scale; CAA, cerebral amyloid angiopathy; OAC, oral anticoagulants; DWM, deep white matter; IVH, intraventricular; oa, on admission; EVD, external ventricular drain. Valid percent: ^ Mann–Whitney U test, * chi-square test, # MCI/dementia vs. healthy cognition. Statistically significant values are given in bold.
Table 2.
Characteristics of patients treated with melatonin vs. the control cohort.
| Patients’ Characteristics | Melatonin Treated n = 119 | Control Cohort n = 220 | p-Value 1 | PSM Control Cohort n = 118 | p-Value 2 | SMD 2 |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age, y median, (IQR) | 76.00 (18.00) | 74.00 (21.00) | 0.059 | 74.50 (22.00) | 0.136 ^ | 0.014 |
| Sex, n (%) | 0.536 * | 0.597 * | 0.053 | |||
| Male | 68 (57.1) | 118 (53.6) | 71 (60.2) | |||
| Female | 51 (42.9) | 102 (46.4) | 47 (39.8) | |||
| Risk Factors, n (%) | ||||||
| HP | 101 (84.9) | 167 (75.9) | 0.053 * | 93 (78.8) | 0.238 * | 0.159 |
| DM | 19 (16.0) | 45 (20.5) | 0.314 * | 27 (22.9) | 0.189 * | 0.175 |
| HCL | 34 (28.1) | 33 (15.0) | 0.003 * | 24 (20.3) | 0.131 * | 0.116 |
| AF | 32 (26.9) | 62 (28.2) | 0.800 * | 38 (32.2) | 0.393 * | 0.183 |
| CAD | 26 (21.8) | 34 (15.5) | 0.146 * | 22 (18.8) | 0.539 * | 0.075 |
| Obesity (BMI > 30) | 20 (16.8) | 41 (18.6) | 0.676 * | 24 (20.3) | 0.504 * | 0.090 |
| Chronic renal failure | 15 (12.6) | 23 (10.5) | 0.549 * | 14 (11.9) | 0.843 * | 0.021 |
| Chronic hepatic failure | 2 (1.7) | 6 (2.7) | 0.545 * | 3 (2.5) | 0.651 * | 0.056 |
| Smoking | 14 (11.8) | 32 (14.5) | 0.475 * | 23 (19.5) | 0.107 * | 0.213 |
| Alcohol | 10 (8.4) | 17 (7.5) | 0.826 * | 10 (8.5) | 1.000 * | 0.004 |
| Malignancy | 13 (10.9) | 23 (10.5) | 0.893 * | 15 (12.7) | 0.687 * | 0.056 |
| Depression | 6 (5.0) | 15 (6.8) | 0.517 * | 7 (5.9) | 0.775 * | 0.040 |
| Cognition | 0.822 *# | 0.393 *# | 0.107 | |||
| Health | 106 (89.1) | 195 (89.9) | 107 (92.2) | |||
| MCI | 11 (9.2) | 20 (9.2) | 9 (7.8) | |||
| Dementia | 2 (1.7) | 2 (0.9) | 0 (0.0) | |||
| Any kind of infection | 55 (46.2) | 121 (55.0) | 0.122 * | 61 (51.7) | 0.436 * | 0.110 |
| Baseline clinical variables/scales | ||||||
| NIHSS oa, median (IQR) | 5.00 (8.0) | 9.00 (11.00) | <0.001 ^ | 6.00 (9.00) | 0.076 ^ | 0.029 |
| Aphasia oa, n (%) | 38 (31.9) | 87 (40.5) | 0.123 * | 42 (35.6) | 0.582 * | 0.078 |
| ICH-score oa, median (IQR) | 1.00 (2.00) | 2.00 (1.00) | 0.003 ^ | 1.00 (1.00) | 0.097 ^ | 0.213 |
| mRS before the ICH, median (IQR) | 0.00 (1.00) | 1.00 (2.00) | 0.128 ^ | 0.00 (2.00) | 0.524 ^ | 0.000 |
| Etiology | ||||||
| Hypertension | 69 (58.0) | 122 (55.5) | 0.645 * | 66 (55.9) | 0.693 * | 0.042 |
| CAA | 12 (10.1) | 15 (6.8) | 0.289 * | 7 (5.9) | 0.232 * | 0.155 |
| Mass | 9 (7.6) | 17 (7.9) | 0.957 * | 9 (7.6) | 1.000 * | 0.000 |
| OAC | 42 (35.3) | 50 (22.7) | 0.013 * | 32 (27.1) | 0.161 * | 0.178 |
| Vessel pathology | 4 (3.4) | 16 (7.3) | 0.145 * | 10 (8.5) | 0.098 * | 0.217 |
| Other/unknown | 25 (21.0) | 42 (19.1) | 0.672 * | 17 (14.4) | 0.229 * | 0.174 |
| Location at baseline | ||||||
| DWM | 53 (45.3) | 104 (47.3) | 0.730 * | 57 (48.3) | 0.689 * | 0.060 |
| Lobar | 47 (39.5) | 92 (41.8) | 0.678 * | 43 (36.4) | 0.687 * | 0.064 |
| Brainstem | 3 (2.5) | 15 (6.8) | 0.093 * | 10 (8.5) | 0.046 * | 0.265 |
| Cerebellum | 15 (12.6) | 26 (11.9) | 0.856 * | 16 (13.7) | 0.827 * | 0.033 |
| Left hemisphere | 68 (57.1) | 114 (51.8) | 0.348 * | 70 (59.3) | 0.792 * | 0.045 |
| Right hemisphere | 56 (47.1) | 118 (53.6) | 0.247 * | 56 (47.5) | 0.896 * | 0.008 |
| IVH oa | 1 (0.8) | 4 (1.8) | 0.476 * | 3 (2.5) | 0.313 * | 0.134 |
| IVH extension | 40 (33.6) | 99 (45.4) | 0.035 * | 48 (40.7) | 0.282 * | 0.147 |
| ICH Volume (cm3) | 8.00 (12.00) | 13 (27.00) | 0.004 ^ | 7.00 (22.00) | 0.997 ^ | 0.009 |
| Invasive procedures, n (%) | ||||||
| Surgical evacuation | 8 (6.7) | 41 (18.6) | 0.003 * | 13 (11.0) | 0.161 * | 0.152 |
| EVD | 9 (7.6) | 40 (18.3) | 0.007 * | 14 (11.9) | 0.272 * | 0.145 |
ICH, intracerebral hemorrhage; PSD, post-stroke delirium; PSM, propensity-score matched; SMD, standardized mean difference (absolute values); HP, hypertension; DM, diabetes mellitus; HCL, hypercholesterolemia; AF, atrial fibrillation; CAD, coronary artery disease; BMI, body mass index; MCI, mild cognitive impairment; NIHSS, National Institutes of Health Stroke Scale; oa, on admission; mRS, modified Rankin scale; CAA, cerebral amyloid angiopathy; OAC, oral anticoagulants; DWM, deep white matter; IVH, intraventricular; EVD, external ventricular drain. Valid percent: ^ Mann–Whitney U test, * chi-square test, # MCI/dementia vs. healthy cognition. 1 Comparison between melatonin-treated cohort and control group. 2 Comparison between melatonin-treated cohort and PSM control group. Statistically significant values are given in bold.
Table 3.
Characteristics of patients with post-ICH PSD treated with melatonin vs. the control cohort after propensity matching.
Table 3.
Characteristics of patients with post-ICH PSD treated with melatonin vs. the control cohort after propensity matching.
| Patients’ Characteristics | PSD Melatonin Treated n = 57 | PSD Control Cohort n = 31 | p-Value |
|---|---|---|---|
| Demographics | |||
| Age, y median, (IQR) | 80.00 (16.00) | 79.00 (16.00) | 0.624 ^ |
| Sex, n (%) | 0.640 * | ||
| Male | 32 (56.1) | 19 (61.3) | |
| Female | 25 (43.9) | 12 (38.7) | |
| Risk Factors, n (%) | |||
| HP | 51 (89.5) | 25 (80.6) | 0.249 * |
| DM | 12 (21.1) | 8 (25.8) | 0.611 * |
| HCL | 19 (33.3) | 6 (19.4) | 0.165 * |
| AF | 19 (33.3) | 14 (45.2) | 0.274 * |
| CAD | 15 (26.3) | 9 (29.0) | 0.785 * |
| Obesity (BMI > 30) | 10 (17.5) | 6 (19.4) | 0.833 * |
| Chronic renal failure | 8 (14.0) | 4 (12.9) | 0.883 * |
| Chronic hepatic failure | 1 (1.8) | 0 (0.0) | 0.458 * |
| Smoking | 6 (10.5) | 5 (16.1) | 0.448 * |
| Alcohol | 7 (12.3) | 1 (3.2) | 0.158 * |
| Malignancy | 4 (7.0) | 4 (12.9) | 0.359 * |
| Depression | 2 (3.5) | 3 (9.7) | 0.232 * |
| Cognition | 0.570 *# | ||
| Health | 47 (82.5) | 27 (87.1) | |
| MCI | 8 (14.0) | 4 (12.9) | |
| Dementia | 2 (3.5) | 0 (0.0) | |
| Any kind of infection | 33 (57.9) | 0.067 * | |
| Baseline clinical variables/scales | |||
| NIHSS oa, median (IQR) | 6.00 (8.00) | 10.00 (8.00) | 0.018 ^ |
| Aphasia oa, n (%) | 20 (35.1) | 16 (51.6) | 0.132 * |
| ICH-score oa, median (IQR) | 2.00 (1.00) | 2.00 (1.00) | 0.305 ^ |
| mRS before the ICH, median (IQR) | 0.50 (3.00) | 0.00 (1.00) | 0.190 ^ |
| Etiology | |||
| Hypertension | 39 (68.4) | 18 (58.1) | 0.331 * |
| CAA | 7 (12.3) | 3 (9.7) | 0.713 * |
| Mass | 2 (3.5) | 4 (12.9) | 0.095 * |
| OAC | 24 (42.1) | 10 (32.3) | 0.365 * |
| Vessel pathology | 0 (0.40) | 0 (0.0) | NA * |
| Other/unknown | 9 (15.8) | 4 (12.9) | 0.715 * |
| Location at baseline | |||
| DWM | 31 (54.4) | 14 (45.2) | 0.408 * |
| Lobar | 20 (35.1) | 13 (41.9) | 0.526 * |
| Brainstem | 0 (0.0) | 2 (6.5) | 0.054 * |
| Cerebellum | 6 (10.5) | 4 (12.9) | 0.737 * |
| Left hemisphere | 32 (56.1) | 18 (58.1) | 0.862 * |
| Right hemisphere | 27 (47.4) | 13 (41.9) | 0.625 * |
| IVH oa | 1 (1.8) | 0 (0.0) | 0.458 * |
| IVH extension | 28 (49.1) | 16 (51.6) | 0.823 * |
| ICH Volume (cm3) | 9.00 (17.00) | 10.00 (23.00) | 0.958 ^ |
| Invasive procedures, n (%) | |||
| Surgical evacuation | 1 (1.8) | 2 (6.5) | 0.246 * |
| EVD | 5 (8.8) | 5 (16.1) | 0.299 * |
ICH, intracerebral hemorrhage; PSD, post-stroke delirium; HP, hypertension; DM, diabetes mellitus; HCL, hypercholesterolemia; AF, atrial fibrillation; CAD, coronary artery disease; BMI, body mass index; MCI, mild cognitive impairment; NIHSS, National Institutes of Health Stroke Scale; oa, on admission; mRS, modified Rankin scale; CAA, cerebral amyloid angiopathy; OAC, oral anticoagulants; DWM, deep white matter; IVH, intraventricular; EVD, external ventricular drain. Valid percent: ^ Mann–Whitney U test, * chi-square test, # MCI/dementia vs. healthy cognition. Statistically significant values are given in bold.
Table 4.
Effect of melatonin administration on PSD duration.
| PSD Cohort | ||
|---|---|---|
| PSD Duration | B (95CI) | p-Value |
| Unadjusted | −0.189 (−0.407–0.029) | 0.088 |
| Adjusted ^ | −0.071 (−0.273–0.131) | 0.486 |
Table 5.
Effect of melatonin administration on SU-stay duration.
| PSD Cohort | Non-PSD Cohort | |||
|---|---|---|---|---|
| SU-Stay Duration | B (95CI) | p-Value | B (95CI) | p-Value |
| Unadjusted | −0.147 (−0.278–−0.016) | 0.028 | −0.004 (−0.114–0.123) | 0.941 |
| Adjusted * | −0.094 (−0.207–0.020) | 0.104 | 0.036 (−0.60–0.131) | 0.460 |
SU, stroke unit; B, unstandardized correlation coefficient; CI, confidence interval; PSD, post-stroke delirium. * The PSD group adjusted for the variables that significantly correlated with SU-stay duration (Table S2) or differed between treated and control PSM PSD groups (Table 3). The non-PSD group is adjusted for the variables that significantly correlated with SU-stay duration (Table S2) or differed between treated and control PSM non-PSD groups (Table S3). Statistically significant values are given in bold.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Siokas, V.; Roesch, S.; Stefanou, M.-I.; Buesink, R.; Wilke, V.; Sartor-Pfeiffer, J.; Adeyemi, K.; Poli, S.; Dardiotis, E.; Ziemann, U.; et al. Effects of Melatonin Administration on Post-Stroke Delirium in Patients with Intracerebral Hemorrhage. J. Clin. Med. 2023, 12, 1937. https://doi.org/10.3390/jcm12051937
AMA Style
Siokas V, Roesch S, Stefanou M-I, Buesink R, Wilke V, Sartor-Pfeiffer J, Adeyemi K, Poli S, Dardiotis E, Ziemann U, et al. Effects of Melatonin Administration on Post-Stroke Delirium in Patients with Intracerebral Hemorrhage. Journal of Clinical Medicine. 2023; 12(5):1937. https://doi.org/10.3390/jcm12051937
Chicago/Turabian StyleSiokas, Vasileios, Sara Roesch, Maria-Ioanna Stefanou, Rebecca Buesink, Vera Wilke, Jennifer Sartor-Pfeiffer, Kamaldeen Adeyemi, Sven Poli, Efthimios Dardiotis, Ulf Ziemann, and et al. 2023. "Effects of Melatonin Administration on Post-Stroke Delirium in Patients with Intracerebral Hemorrhage" Journal of Clinical Medicine 12, no. 5: 1937. https://doi.org/10.3390/jcm12051937
APA StyleSiokas, V., Roesch, S., Stefanou, M.-I., Buesink, R., Wilke, V., Sartor-Pfeiffer, J., Adeyemi, K., Poli, S., Dardiotis, E., Ziemann, U., Feil, K., & Mengel, A. (2023). Effects of Melatonin Administration on Post-Stroke Delirium in Patients with Intracerebral Hemorrhage. Journal of Clinical Medicine, 12(5), 1937. https://doi.org/10.3390/jcm12051937
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
